More than a year after the Food and Drug Administration barred 23andMe from marketing a broad-based genetic testing service, it looks like the FDA plans to shift gears and allow such tests to be sold directly to consumers.
The announcement came in a release today from the regulator that said it’s authorizing 23andMe to market a specific test to consumers for Bloom Syndrome, a rare inherited disorder associated with short stature and various cancers that often result in death by the mid-20s. The genetic testing company had submitted the test for FDA approval last June.
Read More